Laser Photonics, Inc.
This article was originally published in The Gray Sheet
Raises approximately $9.3 mil. in private placement of restricted common stock shares at $4.50 each to institutional and accredited investors. Pennsylvania Merchant Group served as placement agent. Net proceeds will support clinical trials and marketing of the firm's excimer laser treatment for psoriasis; initial testing is complete, and a 510(k) submission is planned. Funds also will go towards manufacturing expenses and working capital. The Carlsbad, California firm is also developing a transmyocardial revascularization application for its excimer laser technology through an alliance with Baxter. Phase II trials will begin later this year
You may also be interested in...
Acculase subsidiary anticipates U.S. launch of its excimer laser system for the treatment of dermatological disorders including psoriasis in early 2000 following submission of a 510(k) to FDA on Aug. 31 (1"The Gray Sheet" Aug. 30, p. 23)
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.